206 related articles for article (PubMed ID: 1830248)
21. Etanidazole as a modulator of combined modality therapy in the rat 9l-gliosarcoma.
Teicher B; Holden S; Ara G; Sotomayor E; Menon K; Tarbell N; Sallan S
Int J Oncol; 1992 Nov; 1(6):625-30. PubMed ID: 21584591
[TBL] [Abstract][Full Text] [Related]
22. Influence of schedule on alkylating agent cytotoxicity in vitro and in vivo.
Teicher BA; Holden SA; Eder JP; Brann TW; Jones SM; Frei E
Cancer Res; 1989 Nov; 49(21):5994-8. PubMed ID: 2790813
[TBL] [Abstract][Full Text] [Related]
23. Interaction of D,L- and D-tetraplatin with hyperthermia in vitro and in vivo.
Epelbaum R; Teicher BA; Holden SA; Ara G; Varshney A; Herman TS
Eur J Cancer; 1992; 28A(4-5):794-800. PubMed ID: 1524897
[TBL] [Abstract][Full Text] [Related]
24. In vivo therapeutic potential of combination thiol depletion and alkylating chemotherapy.
Siemann DW; Beyers KL
Br J Cancer; 1993 Dec; 68(6):1071-9. PubMed ID: 8260357
[TBL] [Abstract][Full Text] [Related]
25. Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro.
Rosbe KW; Brann TW; Holden SA; Teicher BA; Frei E
Cancer Chemother Pharmacol; 1989; 25(1):32-6. PubMed ID: 2590999
[TBL] [Abstract][Full Text] [Related]
26. Acute in vivo resistance in high-dose therapy.
Teicher BA; Ara G; Keyes SR; Herbst RS; Frei E
Clin Cancer Res; 1998 Feb; 4(2):483-91. PubMed ID: 9516940
[TBL] [Abstract][Full Text] [Related]
27. Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Fujimoto S
Biol Pharm Bull; 2006 Nov; 29(11):2260-6. PubMed ID: 17077525
[TBL] [Abstract][Full Text] [Related]
28. Interleukin 1 alpha (IL-1) and macrophage colony-stimulating factor (M-CSF) accelerate recovery from multiple drug-induced myelosuppression.
Kovacs CJ; Kerr JA; Daly BM; Evans MJ; Johnke RM
Anticancer Res; 1998; 18(3A):1805-12. PubMed ID: 9673408
[TBL] [Abstract][Full Text] [Related]
29. Transforming growth factor-beta in in vivo resistance.
Teicher BA; Holden SA; Ara G; Chen G
Cancer Chemother Pharmacol; 1996; 37(6):601-9. PubMed ID: 8612316
[TBL] [Abstract][Full Text] [Related]
30. Potentiation by interleukin 1 alpha of cisplatin and carboplatin antitumor activity: schedule-dependent and pharmacokinetic effects in the RIF-1 tumor model.
Chang MJ; Yu WD; Reyno LM; Modzelewski RA; Egorin MJ; Erkmen K; Vlock DR; Furmanski P; Johnson CS
Cancer Res; 1994 Oct; 54(20):5380-6. PubMed ID: 7923169
[TBL] [Abstract][Full Text] [Related]
31. Schedule-dependent and -independent antitumor activity of paclitaxel-based combination chemotherapy against M-109 murine lung carcinoma in vivo.
Fujimoto S; Chikazawa H
Jpn J Cancer Res; 1998 Dec; 89(12):1343-51. PubMed ID: 10081496
[TBL] [Abstract][Full Text] [Related]
32. [Combination therapy of a new platinum complex, DWA2114R with various antitumor agents against mouse tumors in vivo].
Akamatsu K; Endo K; Tsunenari T; Matsumoto T; Kaiho S; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Gan To Kagaku Ryoho; 1992 Feb; 19(2):229-35. PubMed ID: 1736835
[TBL] [Abstract][Full Text] [Related]
33. Synergism between alkylating agent and cis-platin with moderate local hyperthermia: the effect of multidrug chemotherapy in an animal system.
Matsushita S; Reynolds R; Urano M
Int J Hyperthermia; 1993; 9(2):285-96. PubMed ID: 8468510
[TBL] [Abstract][Full Text] [Related]
34. A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.
Bailey H; Mulcahy RT; Tutsch KD; Rozental JM; Alberti D; Arzoomanian RZ; Tombes MB; Trump DL; Wilding G
Cancer Res; 1991 Feb; 51(4):1099-104. PubMed ID: 1825475
[TBL] [Abstract][Full Text] [Related]
35. Synergistic enhancement by interleukin-1 alpha of cisplatin-mediated antitumor activity in RIF-1 tumor-bearing C3H/HeJ mice.
Johnson CS; Chang MJ; Yu WD; Modzelewski RA; Grandis JR; Vlock DR; Furmanski P
Cancer Chemother Pharmacol; 1993; 32(5):339-46. PubMed ID: 8339383
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-1alpha synergistic in vivo enhancement of cyclophosphamide- and carboplatin-mediated antitumor activity.
Yu WD; Chang MJ; Trump DL; Johnson CS
Cancer Immunol Immunother; 1997 Aug; 44(6):316-22. PubMed ID: 9298933
[TBL] [Abstract][Full Text] [Related]
37. Combination of the minor groove-binder U73-975 or the intercalator mitoxantrone with antitumor alkylating agents in MCF-7 or MCF-7/CP cells.
Ayash L; Korbut T; Herman TS; Teicher BA
Cancer Lett; 1991 Dec; 61(1):7-14. PubMed ID: 1764699
[TBL] [Abstract][Full Text] [Related]
38. Diethyldithiocarbamate inhibition of murine bone marrow toxicity caused by cis-diamminedichloroplatinum(II) or diammine-(1,1-cyclobutanedicarboxylato)platinum(II).
Gringeri A; Keng PC; Borch RF
Cancer Res; 1988 Oct; 48(20):5708-12. PubMed ID: 2844391
[TBL] [Abstract][Full Text] [Related]
39. Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo.
Kusumoto T; Holden SA; Ara G; Teicher BA
Int J Hyperthermia; 1995; 11(4):575-86. PubMed ID: 7594810
[TBL] [Abstract][Full Text] [Related]
40. Combinations of 4-hydroperoxycyclophosphamide (4-HC) and cisplatin for bone marrow purging in autologous marrow transplantation: an update.
Peters RH; Brandon CS; Avila LA; Gale GR; Stuart RK
Prog Clin Biol Res; 1990; 333():57-68. PubMed ID: 2309001
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
